SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing extreme volatility and record volume as the community debates the impact of a lawsuit from Novo Nordisk over its compounded GLP-1 medication and Hims' subsequent withdrawal of the product. Bulls view the steep drop as an oversold buying opportunity, while bears anticipate further declines amid escalating legal and regulatory pressures, especially as Novo Nordisk itself faces an FDA warning regarding its Wegovy ad.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending after issuing weaker-than-expected revenue guidance for the current quarter and fiscal year, despite a strong earnings beat, intensifying investor concerns that AI is disrupting the traditional software business model. The community is sharply divided, with many viewing the steep selloff as an overreaction and a buying opportunity given the company's cash position, while others remain cautious about AI's long-term impact on the SaaS sector.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is plummeting amid news of its CFO and General Counsel's departure, delayed financial filings, a reduced 2026 revenue outlook, and an SEC probe into accounting, sparking a community debate between dip-buyers who see an overreaction and others fearing deeper governance issues.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending following its all-stock acquisition of Valaris, a $5.8 billion deal set to create a combined $17 billion offshore drilling industry leader. The community is actively discussing the potential for a strengthened fleet and significant cost savings to capitalize on an emerging upcycle, though some express concerns over shareholder dilution.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending due to a striking disconnect between recent strong earnings, profitability, and a $500M share buyback, and an unprecedented streak of red daily candles pushing the stock to historic lows. Community sentiment is fiercely divided on whether this presents a generational buying opportunity fueled by its AI/AR smartglasses vision and a potential short squeeze, or if persistent management issues will continue to suppress its value.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending down sharply after its mixed Q4 earnings report, featuring a revenue miss and conservative forward guidance. This has ignited intense community debate over whether the fintech stock is now severely undervalued and a buying opportunity, or if the market is overreacting amidst broader sector weakness.

Tokenized asset from Ondo Finance representing BigBear.ai Holdings (Ondo Tokenized).

BigBear.ai Holdings (Ondo Tokenized Stocks)

BigBear.ai Holdings (Ondo Tokenized Stocks) is trending as the community actively discovers and discusses this tokenized asset, prompting questions about its existence, the broader implications of such financial instruments, and its potential relationship to the underlying NYSE-listed BBAI stock.

Elastic NV is a data analytics company, which engages in the provision of open-source search and analytics engine services. It operates through the United States, the Netherlands, United Kingdom, India, and Rest of World geographical segments. The company was founded by Shay Banon, Uri Boness, Steven Schuurman, and Simon Willnauer on February 9, 2012 and is headquartered in San Francisco, CA.

Elastic N.V

Elastic (ESTC) is seeing intense discussion after strong financial results and the announcement of a $500 million share repurchase program, signaling confidence in its AI and cloud search platform. The market is weighing numerous analyst upgrades and expanding AI adoption against some community concerns regarding recent guidance and sustained profitability.

AECOM engages in the design, manufacture, financing, and operation of infrastructure assets for governments, businesses, and organizations. It operates through the following segments: Americas, International, and AECOM Capital. The Americas segment deals with planning, consulting, architectural and engineering design, construction management, and program management services to public and private clients in the United States, Canada, and Latin America in major end markets such as transportation, water, government, facilities, environmental, and energy. The International segment focuses on planning, consulting, architectural and engineering design services and program management to public and private clients in Europe, the Middle East, India, Africa, and the Asia-Australia-Pacific regions in major end markets such as transportation, water, government, facilities, environmental, and energy. The AECOM Capital segment is involved in investing and developing real estate projects. The company was founded on January 31, 1980 and is headquartered in Dallas, TX.

AECOM

AECOM is trending following strong earnings reports, record backlogs, and substantial global infrastructure contract wins, notably in environmental services and smart city development through its partnership with Gorilla Technology. The company's increased dividend and share buyback program, alongside its strategic focus on high-margin services, are fueling community discussion about its potential as an undervalued play in the ongoing infrastructure boom.

Valaris Ltd. engages in the provision of offshore contract drilling services to the international oil and gas industry. It operates through the following segments: Floaters, Jackups, ARO, and Other. The Floaters segment includes drillships and semisubmersible rigs. The Other segment is involved in management services on rigs owned by third-parties and the activities associated with arrangements with ARO under the bareboat charter arrangements. The company was founded in 1975 and is headquartered in Hamilton, Bermuda.

Valaris Ltd

Valaris is trending following its all-stock acquisition by Transocean, a deal prompting active community discussions about the future of offshore drilling and the treatment of Valaris's warrants, alongside strong recent contract awards that bolster its long-term backlog.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Positive Forecast for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Greenwich LifeSciences in a report released on...

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Time to Sell?

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% - Here's Why...

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% - Here's What Happened

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Here's What Happened...

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

<ul class="summary-bullets"><li>The company is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100.</li><li>The approval follows the submission of manufacturing and stability data tied to multiple production runs.</li><li>More than 1,000 patients have already been screened for FLAMINGO-01.</li></ul>Greenwich LifeSciences, Inc. (GLSI) announced on Thursday that it has cleared another regulatory step in the development of its breast cancer immunotherapy as the company advances its late-stage clinical program.&nbsp;The clinical-stage biotechnology firm is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100, a therapy designed to reduce the risk of cancer returning in certain breast cancer patients.<h2 class="st-heading-2">FDA Manufacturing Clearance</h2>The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.&nbsp;Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences stock</a> traded over 16% higher in Thursday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;The approval follows the submission of manufacturing and stability data tied to multiple production runs completed over the past two years.<blockquote>"With our manufacturing investments in 2023 and 2024, and now the FDA's review and approval to use the first commercial lot of finished GP2 vials in FLAMINGO-01, we have taken major steps to further de-risk the filing of a BLA in the US.”-Snehal Patel, CEO, Greenwich LifeSciences</blockquote><h2 class="st-heading-2">Trial Progress And Early Signals</h2>More than 1,000 patients have already been screened for FLAMINGO-01, with enrollment continuing at a steady pace. One treatment arm involving patients without the HLA-A*02 marker has now completed enrollment, providing a larger dataset than earlier mid-stage research.&nbsp;Preliminary observations following the initial dosing period suggest a sharp decline in recurrence rates, though the company cautioned that the findings remain early and incomplete.GLSI stock has gained over 75% higher in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-retail-chatter-up-in-a-week-what-is-driving-trader-interest/cmUzw1HR4Qo">Ondas Retail Chatter Up 131% In A Week — What's Driving Trader Interest?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Greenwich LifeSciences Stock Soar Pre-Market Today?

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 

GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial

Equity

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 


Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 1,800 shares of the stock in a transaction dated Tuesday, January 13th. The stock was purchased at an average...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 2,900 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 2,900 shares of the company's stock in a transaction dated Monday, January 12th. The shares were acquired at an...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 2,900 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 2,900 shares of the business's stock in a transaction that occurred on Monday, January 12th. The shares were...

Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $91,848.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,300 shares of Greenwich LifeSciences stock in a transaction that occurred on Wednesday, December 31st. The...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,300 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was acquired at an...

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

GLSI
Greenwich LifeSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLSI News

GLSIGreenwich LifeSciences Inc